Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge

Pandemic Affected Trial Results

 
• By Andrew McConaghie

Sanofi and AstraZeneca’s antibody nirsevimab is still likely to reach the market first, but Pfizer could be close behind with superior efficacy results.

RSV patient
Cases of RSV have rebounded after the pandemic lockdowns were lifted • Source: Alamy

More from Business

More from Scrip